Lipocomb (Ezetimibe, Rosuvastatin Zinc)

• Lipocomb acts on lipid metabolism pathways to manage elevated cholesterol levels and associated cardiovascular risk.
• Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels.
• Mixed dyslipidemia: improves the overall lipid profile, lowering triglycerides and raising HDL‑cholesterol.
• Primary hyperlipidemia: provides long‑term control of abnormal lipid concentrations.
• Prevention of cardiovascular events: decreases the incidence of myocardial infarction and stroke in high‑risk patients.

• Ezetimibe selectively inhibits the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. Rosuvastatin zinc competitively inhibits HMG‑CoA reductase, the rate‑limiting enzyme in hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL particles.

Lipocomb may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Myalgia: muscle aches without weakness.
• Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea.
• Elevated liver enzymes: mild transaminase increases.
• Fatigue: general tiredness.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Hepatotoxicity: significant elevation of liver enzymes or jaundice.
• Acute renal failure: sudden loss of kidney function.
• Allergic reactions: rash, pruritus, or angioedema.
• Myocardial infarction: rare cases of heart attack.
• Severe hypersensitivity: anaphylaxis requiring emergency care.

• Before prescribing Lipocomb, clinicians should evaluate patient history and laboratory parameters.
• Liver function monitoring: assess transaminases before initiation and periodically thereafter.
• Renal impairment assessment: adjust therapy in patients with severe kidney disease.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Drug interactions: review concomitant medications for possible interactions.
• Muscle symptoms vigilance: discontinue if unexplained muscle pain or weakness occurs.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protect from moisture and light.

Lipocomb can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure.
• Cyclosporine: markedly raises rosuvastatin plasma levels, raising myopathy risk.
• Gemfibrozil: enhances risk of rhabdomyolysis when combined.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.
• Warfarin: may require INR monitoring due to potential effect on anticoagulation.
• Niacin: can increase risk of liver enzyme elevations.
• Fibrates (other than gemfibrozil): monitor for muscle toxicity.
• Digoxin: rosuvastatin may increase digoxin concentrations.